Mirror Box Therapy for Upper Limb Function With Stroke
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02276729 |
Recruitment Status :
Completed
First Posted : October 28, 2014
Last Update Posted : December 14, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cerebrovascular Accident (CVA) Stroke | Other: Mirror Box Therapy | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | A Pilot Randomized Controlled Trial (RCT) of Mirror Box Therapy in Upper Limb Rehabilitation With Sub-acute Stroke Patients |
Study Start Date : | April 2015 |
Actual Primary Completion Date : | May 31, 2018 |
Actual Study Completion Date : | October 11, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Mirror Box Treatment Group
Participants in the intervention group will be required to perform two 20 minute sessions of Mirror Box Therapy, five days/week for the duration of their in-patient stay carried out under the direction of members of the OT stroke team as well as receiving their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
|
Other: Mirror Box Therapy
Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function. |
No Intervention: Conventional Therapy Control Group
Participants in the control group shall receive their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
|
- Change in Functional Independence Measure v4 at 6 weeks [ Time Frame: Baseline and 6 weeks. ]The FIM/FAM (Version 4) is an 18 item measure of 6 areas of function (self-care; sphincter control; mobility; locomotion; communication and social cognition) grouped into two domains of motor items and cognitive items. Each item is scored on a 7-point likert scale and the score indicates the amount of assistance required to perform each item (ranging from 1 representing total assistance in all areas to 7 representing total independence in all areas), and has been widely used post-stroke18.
- Change in Functional Independence Measure v4 at 3 months post-discharge [ Time Frame: Baseline and 3 months ]The FIM/FAM (Version 4) is an 18 item measure of 6 areas of function (self-care; sphincter control; mobility; locomotion; communication and social cognition) grouped into two domains of motor items and cognitive items. Each item is scored on a 7-point likert scale and the score indicates the amount of assistance required to perform each item (ranging from 1 representing total assistance in all areas to 7 representing total independence in all areas), and has been widely used post-stroke18.
- Change in Functional Independence Measure v4 at 6 months post-discharge [ Time Frame: Baseline and 6 months ]The FIM/FAM (Version 4) is an 18 item measure of 6 areas of function (self-care; sphincter control; mobility; locomotion; communication and social cognition) grouped into two domains of motor items and cognitive items. Each item is scored on a 7-point likert scale and the score indicates the amount of assistance required to perform each item (ranging from 1 representing total assistance in all areas to 7 representing total independence in all areas), and has been widely used post-stroke18.
- Change in Graded Wolf Motor Function Test (gWMFT) at 6 weeks [ Time Frame: Baseline and 6 weeks. ]The gWMFT is a 15-item standardised measure which determines the motor ability of participants by recording functional movement time (0- 120 seconds per item, total = mean of 15 items, maximum score= 120 seconds) and quality of movement (0-7 Likert scale per item with 0= no movement, to 7 = normal movement, total = mean of 15 items, maximum score= 7). This graded version has two levels of each task which can be chosen depending on the participants' general functioning level. The graded version was developed from the original WMFT which has shown to have good reliability and validity. Despite being named a motor assessment, this assessment includes assessment of the upper limb using functional activities and, as such, is considered of relevance to OT outcomes. This outcome measure has also been used by other investigators in previous studies with a stroke cohort.
- Change in Graded Wolf Motor Function Test (gWMFT) at 3 months post-discharge [ Time Frame: Baseline and 3 months. ]The gWMFT is a 15-item standardised measure which determines the motor ability of participants by recording functional movement time (0- 120 seconds per item, total = mean of 15 items, maximum score= 120 seconds) and quality of movement (0-7 Likert scale per item with 0= no movement, to 7 = normal movement, total = mean of 15 items, maximum score= 7). This graded version has two levels of each task which can be chosen depending on the participants' general functioning level. The graded version was developed from the original WMFT which has shown to have good reliability and validity. Despite being named a motor assessment, this assessment includes assessment of the upper limb using functional activities and, as such, is considered of relevance to OT outcomes. This outcome measure has also been used by other investigators in previous studies with a stroke cohort.
- Change in Graded Wolf Motor Function Test (gWMFT) at 6 months post-discharge [ Time Frame: Baseline and 6 months. ]The gWMFT is a 15-item standardised measure which determines the motor ability of participants by recording functional movement time (0- 120 seconds per item, total = mean of 15 items, maximum score= 120 seconds) and quality of movement (0-7 Likert scale per item with 0= no movement, to 7 = normal movement, total = mean of 15 items, maximum score= 7). This graded version has two levels of each task which can be chosen depending on the participants' general functioning level. The graded version was developed from the original WMFT which has shown to have good reliability and validity. Despite being named a motor assessment, this assessment includes assessment of the upper limb using functional activities and, as such, is considered of relevance to OT outcomes. This outcome measure has also been used by other investigators in previous studies with a stroke cohort.
- Change in EQ-5D-5L15 at 6 weeks [ Time Frame: Baseline and 6 weeks. ]The EQ-5D-5L is a widely-used standardized 2 page instrument for use as a measure of health outcome. It is applicable to a wide range of health conditions and treatments and provides a simple descriptive profile of 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) across 5 levels ranging from no problems to extreme problems, and a visual analogue scale of the respondent's self- rated health ranging from 'best imaginable health state' to 'worst imaginable health state'.
- Change in EQ-5D-5L15 at 3 months post-discharge [ Time Frame: Baseline and 3 months. ]The EQ-5D-5L is a widely-used standardized 2 page instrument for use as a measure of health outcome. It is applicable to a wide range of health conditions and treatments and provides a simple descriptive profile of 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) across 5 levels ranging from no problems to extreme problems, and a visual analogue scale of the respondent's self- rated health ranging from 'best imaginable health state' to 'worst imaginable health state'.
- Change in EQ-5D-5L15 at 6 months post-discharge [ Time Frame: Baseline and 6 months. ]The EQ-5D-5L is a widely-used standardized 2 page instrument for use as a measure of health outcome. It is applicable to a wide range of health conditions and treatments and provides a simple descriptive profile of 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) across 5 levels ranging from no problems to extreme problems, and a visual analogue scale of the respondent's self- rated health ranging from 'best imaginable health state' to 'worst imaginable health state'.
- Change in Canadian Occupational Performance Measure (COPM) at 3 months post-discharge [ Time Frame: Baseline and 3 months. ]The COPM is a standardized outcome measure to detect change in a client's self-perception of occupational performance over time. It uses a semi-structured interview format and structured scoring method to detect change scores between assessment and reassessment in everyday occupational activities.
- Change in Canadian Occupational Performance Measure (COPM) at 6 months post-discharge [ Time Frame: Baseline and 6 months. ]The COPM is a standardized outcome measure to detect change in a client's self-perception of occupational performance over time. It uses a semi-structured interview format and structured scoring method to detect change scores between assessment and reassessment in everyday occupational activities.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 years and over;
- newly admitted inpatient of the rehabilitation ward;
- diagnosis of CVA in the last three months resulting in upper limb motor loss;
- able to follow two part spoken or written commands in the English language;
- upper limb therapy designated as a main portion of goal directed treatment programme;
- consent to take part in the study.
Exclusion Criteria:
- patients who have had a previous CVA
- patients who have gross cognitive impairment
- patients who are unable to understand two part spoken/ written commands in English.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02276729
United Kingdom | |
Whiteabbey Hospital, Northern Health and Social Care Trust | |
Belfast, Co Antrim, United Kingdom, BT35 9RH |
Principal Investigator: | Alison Porter-Armstrong, DPhil | University of Ulster, Northern Ireland |
Responsible Party: | Dr Alison Porter-Armstrong, Senior Lecturer in Rehabilitation Sciences, University of Ulster |
ClinicalTrials.gov Identifier: | NCT02276729 |
Other Study ID Numbers: |
165094 |
First Posted: | October 28, 2014 Key Record Dates |
Last Update Posted: | December 14, 2018 |
Last Verified: | December 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Upper limb Rehabilitation Occupational Therapy Mirror Box Therapy |
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |